Abstract library

694 results for "Qian".
#1225 Everolimus in Patients (pts) with Advanced Lung Carcinoids: Evaluation of Median Progression Free Survival (PFS) and Median Time to First Dose Decrease or Discontinuation (DDD)
Introduction: Treatment of well-differentiated (WD) lung neuroendocrine tumors (NETs) is challenging. Everolimus (mTOR inhibitor) has shown encouraging results in digestive NETs but data about its activity on lung carcinoid are sparse.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Letizia Gianoncelli
#890 Prognostic Validity of the WHO 2010 TNM Staging and Grading Criteria for Pancreatic Neuroendocrine Tumors
Introduction: The TNM staging and grading system developed by the WHO was designed to help prognosticate patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Mr Logan E Mills
#893 The Role of Primary Resection and Hepatic Resection in the Management of Metastatic Pancreatic Neuroendocrine Tumors with Irresectable Liver Metastases
Introduction: More than 40% of pancreatic neuroendocrine tumor (PNET) patients have liver metastases (LM) at diagnosis. Whilst it is agreed that, where possible, curative surgery offers the best outcomes, the role of debulking surgery in the context of irresectable LM remains unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Mr Logan E Mills
Keywords: liver
#1244 Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting
Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Michela Del Prete
#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
Authors: Delea T E, Rotter J, Wang X, ...
#350 RAD001 and Octreotide LAR as first-line treatment of well differentiated neuroendocrine tumors: an I.T.M.O. (Italian Trials in Medical Oncology) group study
Introduction: RAD001 has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with somatostatine analogues.
Conference:
Category: Basic
Presenting Author: Dr Laura Catena
#490 Effect of Open-Label Everolimus After Disease Progression in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis
Introduction: In the RADIANT-2 study (NCT00412061), Everolimus + Octreotide LAR (E+O) resulted in a clinically meaningful increase in median progression-free survival (PFS; by adjudicated central review) of 5.1 months v. placebo + Octreotide LAR (P+O) in patients with advanced NET with a history of carcinoid syndrome. Investigator-assessed PFS was 12.0 months for E+O compared with 8.6 months for P+O, respectively. On radiologically confirmed disease progression, P+O patients could cross over to open-label E+O.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dieter Hörsch
Authors: Hörsch D, Luppi G, Jehl V, Peeters M, ...
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan
#1105 Pre-PRRT Uptake on 68Ga-DOTATOC Predicts Good Prognosis in Neuroendocrine Tumors Patients
Introduction: There is a growing need to identify PRRT-responders on an early time point during therapy.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sofie Van Binnebeek
Keywords: PET, response, PRRT
#1197 The Neuron-Specific Enolase Assessment in Patients with Neuroendocrine Tumors with or without Carcinoid Syndrome
Introduction: NeuroEndocrine Tumors (NETs) comprises a wide area of clinical presentations and neuroendocrine markers.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD Mara Carsote